About FDA
-
Acute Leukemia Endpoints Agenda
Presented by the American Society of Hematology and the U.S. Food and Drug Administration
Co-sponsored by the American Association for Cancer Research, American Society of Clinical Oncology, and Southwest Oncology Group
Friday, June 24, 2005
8:30 a.m. – 5:00 p.m.
JW Marriott Hotel Pennsylvania Avenue
Salons F and E
1331 Pennsylvania Avenue, Washington, DC 20004
Ph: (202) 393-2000
AGENDA
8:00 am |
Continental Breakfast Available Registration for Public Comments |
|
| 8:30 am | Welcome and Introductions | Stanley L. Schrier, MD |
| Richard Pazdur, MD | ||
| 8:40 am | Purpose of Conference & Regulatory Background | Nancy Scher, MD |
| 9:00 am | Scope and Background of Panel | Frederick Appelbaum, MD |
| 9:10 am | Scope of Problem/Heterogeneity Component | Frederick Appelbaum, MD |
| 9:30 am | Panel Questions regarding Heterogeneity | Panel |
| 9:50 am | Break | |
| 10:00 am | Definition of Response Component | Susan O’Brien, MD |
| 10:20 am | Panel Questions regarding Definition of Response | Panel |
| 10:40 am | Minimal Residual Disease Component | William L. Carroll, MD |
| 11:00 am | Panel Questions regarding Minimal Residual Disease | Panel |
| 11:20 am | Bridge to Transplant Component | Robert J. Arceci, MD |
| 11:40 am | Panel Questions regarding Bridge to Transplant | Panel |
| 12:00 pm | Lunch Available for all Registered Participants (Garden Terrace) |
|
| 1:00 pm | Quality of Life Component | Philip Breitfeld, MD |
| 1:20 pm | Panel Questions regarding Quality of Life | Panel |
| 1:40 pm | Public Comments | |
| 2:10 pm | Chairs’ Questions to Panel | Frederick Appelbaum, MD Daniel Rosenblum, MD |
-
-
